One potential option is to use treatments licensed for osteoporosis, such as bisphosphonates or receptor activator of nuclear factor kappa-B ligand (RANKL)-inhibitors, which not only improve bone health but have also demonstrated the ability to reduce vascular calcification (80). The gene discussed is TNFSF11; the disease is osteoporosis.